SPOTLIGHT -
Emerging β-Lactamases in Pseudomonas aeruginosa That Threaten the Utility of New β-Lactam/β-Lactamase Inhibitors
Resistance against this pathogen with β-lactamase medications can vary according to geographic region.
Read More
The Yin and Yang of Ceftolozane-Tazobactam Resistance Against Multidrug-Resistant Pseudomonas aeruginosa
Rates of hospital-onset multidrug-resistant P aeruginosa infections have increased significantly in recent years.
Is There a Preferred β-Lactam/β-Lactamase Inhibitor Agent for Treatment of KPC-Producing Enterobacterales Infection?
Carbapenem-resistant Enterobacterales present considerable treatment challenges. Recent cumulative evidence supports preference for therapies.
Hope on the Horizon: Treatment for Carbapenem-Resistant Acinetobacter baumannii Infections
Recent study results show promising new modalities.
Do β-Lactam Prolonged Infusions Suppress the Emergence of Resistance?
This approach can help with clinical outcomes and mortality, but resistance is not as well defined.
Emergence of Ceftazidime-Avibactam Resistance: What Have We Learned in the Past 4 Years?
Ceftazidime-avibactam is a novel treatment for CRE infections, but reports of resistance are increasing.